28525838|t|Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment
28525838|a|Overexpression of EGFR is often associated with advanced stage disease and poor prognosis. In certain cancers, Src works synergistically with EGFR to promote proliferation, survival, invasion and metastasis. Development of dual-target drugs against EGFR and Src is of therapeutic advantage against these cancers. Based on molecular docking and our previous studies, we rationally designed a new series of azaacridine derivatives as potent EGFR and Src dual inhibitors. Most of the synthesized azaacridines displayed good antiproliferative activity against K562 and A549 cells. The representative compound 13b showed nM IC50 values against K562 and A549 cells, and inhibited EGFR at inhibition rate of 33.53% at 10 μM and Src at inhibition rate of 72.12% at 1 μM. Furthermore, compound 13b could inhibit the expression of EGFR, p-EGFR, Src and p-Src. Moreover, 13b efficiently inhibited the invasion of tumor cells and induced cancer cells apoptosis. Our study suggested that azaacridine scaffold can be developed as novel multi-target kinase inhibitors for cancer therapy.
28525838	0	6	Design	T052	C1707689
28525838	8	17	synthesis	T052	C1883254
28525838	36	59	azaacridine derivatives	T109	C0001186
28525838	63	74	dual-target	T169	C1521840
28525838	75	79	EGFR	T116,T126,T192	C0034802
28525838	84	94	Src kinase	T116,T126	C0282625
28525838	95	105	inhibitors	T116,T121	C3537035
28525838	110	119	antitumor	T080	C2986475
28525838	120	129	treatment	T061	C0087111
28525838	130	144	Overexpression	T045	C1514559
28525838	148	152	EGFR	T116,T126,T192	C0034802
28525838	162	177	associated with	T080	C0332281
28525838	178	192	advanced stage	T080	C0205179
28525838	193	200	disease	T047	C0012634
28525838	205	219	poor prognosis	T033	C0278252
28525838	232	239	cancers	T191	C0007097
28525838	241	244	Src	T116,T126	C0282625
28525838	251	266	synergistically	T080	C2986495
28525838	272	276	EGFR	T116,T126,T192	C0034802
28525838	280	287	promote	T052	C0033414
28525838	288	301	proliferation	T043	C0596290
28525838	303	311	survival	T043	C0007620
28525838	313	321	invasion	T046	C2699153
28525838	326	336	metastasis	T046	C4255448
28525838	338	349	Development	T169	C1527148
28525838	353	364	dual-target	T169	C1521840
28525838	365	370	drugs	T121	C0013227
28525838	371	378	against	T080	C0521124
28525838	379	383	EGFR	T116,T126,T192	C0034802
28525838	388	391	Src	T116,T126	C0282625
28525838	398	409	therapeutic	T169	C0302350
28525838	420	427	against	T080	C0521124
28525838	434	441	cancers	T191	C0007097
28525838	443	448	Based	T078	C1705938
28525838	452	469	molecular docking	T170	C3494274
28525838	487	494	studies	T062	C2603343
28525838	510	518	designed	T052	C1707689
28525838	525	531	series	T081	C0205549
28525838	535	558	azaacridine derivatives	T109	C0001186
28525838	569	573	EGFR	T116,T126,T192	C0034802
28525838	578	581	Src	T116,T126	C0282625
28525838	587	597	inhibitors	T116,T121	C3537035
28525838	611	622	synthesized	T052	C1883254
28525838	623	635	azaacridines	T109	C0001186
28525838	636	645	displayed	T169	C0870432
28525838	646	650	good	T080	C0205170
28525838	651	677	antiproliferative activity	T169	C0599112
28525838	678	685	against	T080	C0521124
28525838	686	690	K562	T025	C0600432
28525838	695	705	A549 cells	T025	C4277577
28525838	726	738	compound 13b	T121	C1254351
28525838	749	753	IC50	T081	C0600495
28525838	754	760	values	T080	C0042295
28525838	761	768	against	T080	C0521124
28525838	769	773	K562	T025	C0600432
28525838	778	788	A549 cells	T025	C4277577
28525838	794	803	inhibited	T080	C0311403
28525838	804	808	EGFR	T116,T126,T192	C0034802
28525838	812	822	inhibition	T052	C3463820
28525838	823	827	rate	T081	C1521828
28525838	851	854	Src	T116,T126	C0282625
28525838	858	868	inhibition	T052	C3463820
28525838	869	873	rate	T081	C1521828
28525838	906	918	compound 13b	T121	C1254351
28525838	925	932	inhibit	T052	C3463820
28525838	937	947	expression	T045	C1171362
28525838	951	955	EGFR	T116,T126,T192	C0034802
28525838	957	963	p-EGFR	T116,T126,T192	C0034802
28525838	965	968	Src	T116,T126	C0282625
28525838	973	978	p-Src	T116,T126	C0282625
28525838	990	993	13b	T121	C1254351
28525838	994	1005	efficiently	T080	C0442799
28525838	1006	1015	inhibited	T080	C0311403
28525838	1020	1043	invasion of tumor cells	T033	C1269955
28525838	1048	1055	induced	T169	C0205263
28525838	1056	1068	cancer cells	T025	C0334227
28525838	1069	1078	apoptosis	T043	C0162638
28525838	1084	1089	study	T062	C2603343
28525838	1090	1099	suggested	T078	C1705535
28525838	1105	1116	azaacridine	T109	C0001186
28525838	1117	1125	scaffold	T073	C0337143
28525838	1133	1142	developed	T169	C1527148
28525838	1146	1151	novel	T080	C0205314
28525838	1152	1182	multi-target kinase inhibitors	T116,T121	C3537035
28525838	1187	1201	cancer therapy	T061	C0920425